Advisornet Financial’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-206
| Closed | -$51 | – | 2355 |
|
|
2026
Q1 | $51 | Hold |
206
| – | – | ﹤0.01% | 2223 |
|
|
2025
Q4 | $87 | Hold |
206
| – | – | ﹤0.01% | 2193 |
|
|
2025
Q3 | $139 | Hold |
206
| – | – | ﹤0.01% | 2176 |
|
|
2025
Q2 | $112 | Hold |
206
| – | – | ﹤0.01% | 2170 |
|
|
2025
Q1 | $135 | Hold |
206
| – | – | ﹤0.01% | 2102 |
|
|
2024
Q4 | $210 | Sell |
206
-1,880
| -90% | -$3.44K | ﹤0.01% | 1879 |
|
|
2024
Q3 | $1.81K | Hold |
2,086
| – | – | ﹤0.01% | 1778 |
|
|
2024
Q2 | $747 | Hold |
2,086
| – | – | ﹤0.01% | 1875 |
|
|
2024
Q1 | $1.4K | Hold |
2,086
| – | – | ﹤0.01% | 1672 |
|
|
2023
Q4 | $1.13K | Hold |
2,086
| – | – | ﹤0.01% | 1848 |
|
|
2023
Q3 | $1.25K | Hold |
2,086
| – | – | ﹤0.01% | 1752 |
|
|
2023
Q2 | $2.71K | Hold |
2,086
| – | – | ﹤0.01% | 1647 |
|
|
2023
Q1 | $3.67K | Hold |
2,086
| – | – | ﹤0.01% | 1565 |
|
|
2022
Q4 | $6.55K | Hold |
2,086
| – | – | ﹤0.01% | 1407 |
|
|
2022
Q3 | $10K | Hold |
2,086
| – | – | ﹤0.01% | 1345 |
|
|
2022
Q2 | $9K | Hold |
2,086
| – | – | ﹤0.01% | 1383 |
|
|
2022
Q1 | $12K | Buy |
2,086
+206
| +11% | +$1.23K | ﹤0.01% | 1400 |
|
|
2021
Q4 | $14K | Buy |
+1,880
| New | +$16.3K | ﹤0.01% | 1399 |
|
Other funds holding SGMO
Advisornet Financial's SGMO Position: Q2 2026 in Review
Advisornet Financial sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2026, closing a stake of 206 shares — an estimated $51 sold.
Advisornet Financial first reported a position in SGMO in Q4 2021 and held it in 18 quarters. The position peaked at $14K in Q4 2021. 2 funds tracked by Wall St. Rank hold SGMO as of Q2 2026.
- Advisornet Financial reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2026 after selling out during the quarter.
- Advisornet Financial sold 206 SANGAMO THERAPEUTICS INC shares in Q2 2026, an estimated $51.
- Advisornet Financial first reported a position in SANGAMO THERAPEUTICS INC in Q4 2021 and held it in 18 quarters.
- Advisornet Financial's SANGAMO THERAPEUTICS INC position peaked at $14K in Q4 2021.
- 2 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2026.
Based on Advisornet Financial's 13F filing for Q2 2026, filed 23 Jul 2026.